VantroMarket Overview
← All markets
Health Market Overview

Denmark

Last updated: November 2026
Regulatory Body
Danish Medicines Agency (Laegemiddelstyrelsen, DKMA)
Typical Timeline
60-210 days
Regulatory Overview

Denmark's primary regulatory authority is the Danish Medicines Agency (DKMA), operating under the Ministry of the Interior and Health. Pharmaceutical products are governed by the Danish Medicines Act (Laegemiddelloven, Consolidated Act No. 99 of 16 January 2018 and subsequent amendments), while medical devices and in vitro diagnostics fall under EU Regulations 2017/745 (MDR) and 2017/746 (IVDR), enforced nationally through the Danish Patient Safety Authority (Styrelsen for Patientsikkerhed) in coordination with DKMA. As an EU member state, Denmark participates fully in the European Medicines Agency (EMA) centralized procedure for eligible products, and also accepts the mutual recognition and decentralized procedures for national or multi-state approvals. Digital health solutions may be subject to additional regulatory classification depending on their intended purpose, with software-as-a-medical-device (SaMD) assessed against EU MDR criteria. Health technology assessment (HTA) is conducted by the Danish Medicines Council (Medicinraadet), which provides recommendations on clinical and economic value prior to public reimbursement decisions.

For pharmaceutical submissions, Denmark accepts dossiers in the Common Technical Document (CTD) format aligned with ICH guidelines, as required under EU regulatory frameworks. A local EU-based Qualified Person for Pharmacovigilance (QPPV) and an EU marketing authorization holder or local representative are mandatory requirements. Medical device manufacturers must hold CE marking under the applicable EU regulation, with registration via EUDAMED progressively becoming mandatory. Recent reforms include the full applicability of EU MDR and IVDR, stricter post-market surveillance obligations, and Denmark's active participation in the EU Joint Clinical Assessment (JCA) framework introduced under EU Regulation 2021/2282 on HTA, which came into force in January 2025 for oncology and advanced therapy medicinal products. The DKMA has also advanced digital submission portals and aligned national guidance with EMA's evolving regulatory science strategy.

Procurement Overview

Denmark operates a highly centralized and publicly funded healthcare system, with the state bearing primary responsibility for health financing. The five regions (Capital Region, Region Zealand, Region of Southern Denmark, Central Denmark Region, and North Denmark Region) are the main administrative and purchasing entities for hospital-based health products, including pharmaceuticals, medical devices, and diagnostics. Procurement is coordinated nationally through Amgros I/S, a non-profit procurement organization owned by the five regions, which conducts centralized tender processes for hospital medicines and negotiates framework agreements on behalf of all regional hospitals. Medical devices and equipment procurement may be handled at the regional or hospital level, often through collaborative framework agreements facilitated by SKI (Staten og Kommunernes Indkobscentral), the national procurement cooperative serving both state institutions and municipalities. All public procurement must comply with EU Public Procurement Directives (2014/24/EU and 2014/25/EU), transposed into Danish law via the Public Procurement Act (Udbudsloven, Act No. 1564 of 15 December 2015), ensuring competitive tendering, transparency, and equal treatment of suppliers.

The private healthcare sector in Denmark is relatively modest compared to the public system, but is growing, with private hospitals, clinics, and insurance-funded services representing a secondary procurement channel for health products. Private payers and employers increasingly fund supplementary health insurance schemes, creating additional market access opportunities particularly for diagnostics, digital health tools, and elective medical devices. Denmark does not rely on international donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, given its status as a high-income country and a net donor to global health initiatives. However, Denmark is home to UNICEF Supply Division headquarters in Copenhagen, making it a significant hub for global health procurement expertise. Local manufacturing preference policies are not a formal feature of Danish procurement regulations, as EU single market rules prohibit discriminatory national preferences, though sustainability criteria, environmental standards, and supply chain resilience considerations are increasingly incorporated into tender evaluation frameworks.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Denmark →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.